Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus

Adel Bozorgzadeh, Ashokkumar Jain, Charlotte Ryan, Daniel Ornt, Martin Zand, Parvez Mantry, Kerrie Lansing, Mark Orloff

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background. There has been concern that adult living-donor liver transplantation (LLTx) for hepatitis C virus (HCV) infection may lead to recurrent disease that is more severe compared with the results of cadaveric LTx (CLTx), because the smaller sized graft in LLTx regenerates and may increase viral replication. This study examines the survival outcome and HCV recurrence in CLTx versus LLTx performed at a single institution. Method. A total of 100 consecutive adult recipients (75 men and 25 women; mean age 49.9±8.4 years) of LTx (65 CLTxs and 35 LLTxs performed July 2000-July 2002) who tested positive for HCV by polymerase chain reaction were examined retrospectively until October 2003. All patients received tacrolimus-based immunosuppression with mycophenolate mofetil and steroids. Results. The overall actual patient survival was 85% (83.1% for CLTx vs. 88.6% for LLTx). The 39-month Kaplan-Meier actuarial patient survivals were 75.1% for CLTx and 88.6% for LLTx. Of 15 deaths, 6 were the result of recurrent HCV (five CLTxs and one LLTx), and of 10 retransplants, 2 were related to recurrent HCV (one CLTx and one LLTx). The rates of recurrence were 72.3% and 77.1%, the hepatitis activity indices were 5.4+2.4 and 6.2+2.8, the fibrosis scores were 1.4±1.4 and 1.5±1.3, and the times to recurrence were 318±269 days and 394±250 days for CLTx and LLTx, respectively. None of the differences between the two groups were significant. Conclusion. No detrimental effect of HCV infection was found in LLTx recipients when compared with contemporaneous CLTx recipients. Patient survival, graft survival, rate of HCV recurrence, severity of HCV recurrence, graft loss from HCV, and interval for recurrence in CLTx and LLTx were similar.

Original languageEnglish (US)
Pages (from-to)1066-1070
Number of pages5
JournalTransplantation
Volume77
Issue number7
DOIs
StatePublished - Apr 15 2004

Fingerprint

Living Donors
Tacrolimus
Virus Diseases
Hepatitis C
Hepacivirus
Allografts
Liver
Recurrence
Survival
Mycophenolic Acid
Transplants
Transplant Recipients
Graft Survival
Liver Transplantation
Immunosuppression
Hepatitis
Fibrosis
Survival Rate
Steroids
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Transplantation
  • Immunology

Cite this

Bozorgzadeh, Adel ; Jain, Ashokkumar ; Ryan, Charlotte ; Ornt, Daniel ; Zand, Martin ; Mantry, Parvez ; Lansing, Kerrie ; Orloff, Mark. / Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. In: Transplantation. 2004 ; Vol. 77, No. 7. pp. 1066-1070.
@article{696de9a5489242ddb5ac71ba0d97ae8a,
title = "Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus",
abstract = "Background. There has been concern that adult living-donor liver transplantation (LLTx) for hepatitis C virus (HCV) infection may lead to recurrent disease that is more severe compared with the results of cadaveric LTx (CLTx), because the smaller sized graft in LLTx regenerates and may increase viral replication. This study examines the survival outcome and HCV recurrence in CLTx versus LLTx performed at a single institution. Method. A total of 100 consecutive adult recipients (75 men and 25 women; mean age 49.9±8.4 years) of LTx (65 CLTxs and 35 LLTxs performed July 2000-July 2002) who tested positive for HCV by polymerase chain reaction were examined retrospectively until October 2003. All patients received tacrolimus-based immunosuppression with mycophenolate mofetil and steroids. Results. The overall actual patient survival was 85{\%} (83.1{\%} for CLTx vs. 88.6{\%} for LLTx). The 39-month Kaplan-Meier actuarial patient survivals were 75.1{\%} for CLTx and 88.6{\%} for LLTx. Of 15 deaths, 6 were the result of recurrent HCV (five CLTxs and one LLTx), and of 10 retransplants, 2 were related to recurrent HCV (one CLTx and one LLTx). The rates of recurrence were 72.3{\%} and 77.1{\%}, the hepatitis activity indices were 5.4+2.4 and 6.2+2.8, the fibrosis scores were 1.4±1.4 and 1.5±1.3, and the times to recurrence were 318±269 days and 394±250 days for CLTx and LLTx, respectively. None of the differences between the two groups were significant. Conclusion. No detrimental effect of HCV infection was found in LLTx recipients when compared with contemporaneous CLTx recipients. Patient survival, graft survival, rate of HCV recurrence, severity of HCV recurrence, graft loss from HCV, and interval for recurrence in CLTx and LLTx were similar.",
author = "Adel Bozorgzadeh and Ashokkumar Jain and Charlotte Ryan and Daniel Ornt and Martin Zand and Parvez Mantry and Kerrie Lansing and Mark Orloff",
year = "2004",
month = "4",
day = "15",
doi = "10.1097/01.TP.0000122142.00818.9E",
language = "English (US)",
volume = "77",
pages = "1066--1070",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. / Bozorgzadeh, Adel; Jain, Ashokkumar; Ryan, Charlotte; Ornt, Daniel; Zand, Martin; Mantry, Parvez; Lansing, Kerrie; Orloff, Mark.

In: Transplantation, Vol. 77, No. 7, 15.04.2004, p. 1066-1070.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus

AU - Bozorgzadeh, Adel

AU - Jain, Ashokkumar

AU - Ryan, Charlotte

AU - Ornt, Daniel

AU - Zand, Martin

AU - Mantry, Parvez

AU - Lansing, Kerrie

AU - Orloff, Mark

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Background. There has been concern that adult living-donor liver transplantation (LLTx) for hepatitis C virus (HCV) infection may lead to recurrent disease that is more severe compared with the results of cadaveric LTx (CLTx), because the smaller sized graft in LLTx regenerates and may increase viral replication. This study examines the survival outcome and HCV recurrence in CLTx versus LLTx performed at a single institution. Method. A total of 100 consecutive adult recipients (75 men and 25 women; mean age 49.9±8.4 years) of LTx (65 CLTxs and 35 LLTxs performed July 2000-July 2002) who tested positive for HCV by polymerase chain reaction were examined retrospectively until October 2003. All patients received tacrolimus-based immunosuppression with mycophenolate mofetil and steroids. Results. The overall actual patient survival was 85% (83.1% for CLTx vs. 88.6% for LLTx). The 39-month Kaplan-Meier actuarial patient survivals were 75.1% for CLTx and 88.6% for LLTx. Of 15 deaths, 6 were the result of recurrent HCV (five CLTxs and one LLTx), and of 10 retransplants, 2 were related to recurrent HCV (one CLTx and one LLTx). The rates of recurrence were 72.3% and 77.1%, the hepatitis activity indices were 5.4+2.4 and 6.2+2.8, the fibrosis scores were 1.4±1.4 and 1.5±1.3, and the times to recurrence were 318±269 days and 394±250 days for CLTx and LLTx, respectively. None of the differences between the two groups were significant. Conclusion. No detrimental effect of HCV infection was found in LLTx recipients when compared with contemporaneous CLTx recipients. Patient survival, graft survival, rate of HCV recurrence, severity of HCV recurrence, graft loss from HCV, and interval for recurrence in CLTx and LLTx were similar.

AB - Background. There has been concern that adult living-donor liver transplantation (LLTx) for hepatitis C virus (HCV) infection may lead to recurrent disease that is more severe compared with the results of cadaveric LTx (CLTx), because the smaller sized graft in LLTx regenerates and may increase viral replication. This study examines the survival outcome and HCV recurrence in CLTx versus LLTx performed at a single institution. Method. A total of 100 consecutive adult recipients (75 men and 25 women; mean age 49.9±8.4 years) of LTx (65 CLTxs and 35 LLTxs performed July 2000-July 2002) who tested positive for HCV by polymerase chain reaction were examined retrospectively until October 2003. All patients received tacrolimus-based immunosuppression with mycophenolate mofetil and steroids. Results. The overall actual patient survival was 85% (83.1% for CLTx vs. 88.6% for LLTx). The 39-month Kaplan-Meier actuarial patient survivals were 75.1% for CLTx and 88.6% for LLTx. Of 15 deaths, 6 were the result of recurrent HCV (five CLTxs and one LLTx), and of 10 retransplants, 2 were related to recurrent HCV (one CLTx and one LLTx). The rates of recurrence were 72.3% and 77.1%, the hepatitis activity indices were 5.4+2.4 and 6.2+2.8, the fibrosis scores were 1.4±1.4 and 1.5±1.3, and the times to recurrence were 318±269 days and 394±250 days for CLTx and LLTx, respectively. None of the differences between the two groups were significant. Conclusion. No detrimental effect of HCV infection was found in LLTx recipients when compared with contemporaneous CLTx recipients. Patient survival, graft survival, rate of HCV recurrence, severity of HCV recurrence, graft loss from HCV, and interval for recurrence in CLTx and LLTx were similar.

UR - http://www.scopus.com/inward/record.url?scp=1942504262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942504262&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000122142.00818.9E

DO - 10.1097/01.TP.0000122142.00818.9E

M3 - Article

VL - 77

SP - 1066

EP - 1070

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 7

ER -